Curanex Pharmaceuticals (CURX) Operating Leases (2025)

Curanex Pharmaceuticals' (CURX) quarterly Operating Leases came in at $224010.0 in Q4 2025, up 266.33% on a QoQ basis from $61150.0 in Q3 2025.

Curanex Pharmaceuticals (CURX) Operating Leases (2025) Analysis & Trends

Curanex Pharmaceuticals (CURX) has 1 years of Operating Leases data on file, last reported at $224010.0 in Q4 2025.

Quarterly Operating Leases changed N/A year-over-year to $224010.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $224010.0 (changed N/A YoY) and the FY2025 annual result came in at $224010.0, changed N/A from the prior year.
Operating Leases grew to $224010.0 in Q4 2025, from $61150.0 in the prior quarter.
In the past five years, Operating Leases ranged from a high of $224010.0 in Q4 2025 to a low of $5816.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Curanex Pharmaceuticals	6.11 Mn	1.11 Mn	-

Download Data